Farhana Pruthi

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

Elfrida R. Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu et al. · Genetics in Medicine · 2016 · 207 citations · Full text

ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities

Feng Liu, Steve Grauer, Cody Kelley et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 181 citations

State-Dependent Compound Inhibition of Nav1.2 Sodium Channels Using the FLIPR Vm Dye: On-Target and Off-Target Effects of Diverse Pharmacological Agents

Elfrida R. Benjamin, Farhana Pruthi, Shakira Olanrewaju et al. · SLAS DISCOVERY · 2006 · 36 citations · Full text

Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR

Elfrida R. Benjamin, Farhana Pruthi, Shakira Olanrewaju et al. · Biochemical Pharmacology · 2006 · 29 citations

Molecular Pharmacology, Pharmacological Characterization, Medicine +5

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia

David P. Rotella, Geraldine McFarlane, Alexander Greenfield et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 18 citations · Full text

Psychoactive Drug, Psychiatry, Psychotic Disorder +14